PE/Cyanine7 anti-mouse CD279 (PD-1) Antibody
- 产品名称：
- PE/Cyanine7 anti-mouse CD279 (PD-1) Antibody
- 产品类别：
- 抗体
- 产品编号：
- 135215
- 产品应用：
- 135215
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- PD-1 cDNA followed by PD-1-Ig fusion protein
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
- Concentration
- 0.2 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application Notes
Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.
- Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
- Application References
(PubMed link indicates BioLegend citation) -
- Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
- Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
- Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
- Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
- Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
- Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
- Product Citations
-
- Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
- Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
- Liu J, et al. 2021. Front Immunol. 12:747730. PubMed
- Aggen DH, et al. 2020. Clin Cancer Res. . PubMed
- Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
- Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
- Shi B, et al. 2018. J Immunol. 200:586. PubMed
- Wei H, et al. 2021. Malar J. 20:89. PubMed
- Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
- Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
- Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
- Browning LM, et al. 2020. Cell Rep. 33:108219. PubMed
- Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
- Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
- Wiede F, et al. 2021. Cancer Discov. Online ahead of print. PubMed
- Saumyaa, et al. 2016. J Immunol. 196: 3677 - 3685. PubMed
- Kelsey E Sivick et al. 2018. Cell reports. 25(11):3074-3085 . PubMed
- Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed
- Saumyaa S, et al. 2013. Infect Immun . 81:3426. PubMed
- Grzelak A, et al. 2018. Int J Mol Sci. 19:. PubMed
- Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
- Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
- Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
- Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
- Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
- Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
- Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed
- Ullrich L, et al. 2021. Front Immunol. 12:729607. PubMed
- Moguche AO et al. 2017. Cell host & microbe. 21(6):695-706 . PubMed
- Sandu I, et al. 2020. Cell Reports. 32(8):108078. PubMed
- Blanchard L, et al. 2022. STAR Protoc. 3:101444. PubMed
- Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed
- Dong X, et al. 2022. Front Immunol. 13:896472. PubMed
- Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
- Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
- Zeis P, et al. 2020. Immunity. 53:775. PubMed
- Burton B, et al. 2014. Nat Commun. 5:4741. PubMed
- Yermanos A, et al. 2020. Front Immunol. 1.143055556. PubMed
- Skadow M, et al. 2019. J Immunol. 203:370. PubMed
- Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
- Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
- Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
- Hu J, et al. 2022. J Immunother Cancer. 10:. PubMed
- Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
- Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
- Sheriff L, et al. 2022. STAR Protoc. 11:. PubMed
- NB M, et al. 2017. J Immunol. 198:1142-1155. PubMed
- Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
- Liang Z, et al. 2022. iScience. 25:105233. PubMed
- Trindade BC, et al. 2021. Immunity. 54:2273. PubMed
- Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
- RRID
- AB_10696422 (BioLegend Cat. No. 135215) AB_10689635 (BioLegend Cat. No. 135216)
- Structure
- A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
- Distribution
-
Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.
- Function
- Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
- Ligand/Receptor
- B7-H1 (PD-L1) and B7-DC (PD-L2)
- Cell Type
- B cells, T cells
- Biology Area
- Cancer Biomarkers, Immunology, Inhibitory Molecules
- Molecular Family
- CD Molecules, Immune Checkpoint Receptors
- Antigen References
-
1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313
- Gene ID
- 18566 View all products for this Gene ID
- UniProt
- View information about CD279 on UniProt.org
